Psychedelic microdosing benefits and challenges: an empirical codebook
Thomas Anderson, Rotem Petranker, Adam Christopher, Daniel Rosenbaum, Cory R. Weissman, Lê-Anh Dinh-Williams, Katrina Hui, Emma Hapke
Harm Reduction Journal July 9, 2019 DOI: 10.1186/s12954-019-0308-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Mixed-methods study Peer reviewed |
|---|---|
| Population | Active microdosing community |
| Intervention | Microdosing |
| Topics | LSD Psilocybin Microdosing |
| Keywords | Hallucinogen Popularity Pharmacology |
| Citations | 130 |
| Key points | The MDBC taxonomy distills high-potential intervention targets from participant reports to inform efficient allocation of research funding. |
Abstract
These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come.
In the evidence
This study is part of the evidence base for 3 syntheses in the library. Here is how each one recorded it.
-
Develops a taxonomy of reported microdosing benefits and challenges to identify intervention targets for future research.
Synthesized
-
Argues that a taxonomy of participant-reported microdosing benefits and challenges can frame and prioritize future scientific research.
Synthesized
-
The study developed a taxonomy of microdosing benefits and challenges from participant reports to frame future research priorities.
Synthesized
Comparable studies
Other qualitative studies on LSD and microdosing, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health. People who microdose psychedelic drugs | 2023 | Qualitative study | n = 13 |
| Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures. Individuals with major depressive disorder (MDD) | 2025 | Qualitative study | n = 23 |